What type of study is this?

October 2, 2025

Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

View Full Paper

Ask AI

Bookmark

Treatment resulted in notable tumor response patterns over time, indicating potential effectiveness.
Detailed data reflects treatment duration for patients receiving nelitolimod with pembrolizumab in a cohort.
Observational analysis of response evidenced promising outcomes for novel combination therapies in melanoma.
Findings suggest that further studies are warranted to verify efficacy and optimize treatment protocols.

Implication

Open-label trial assessed treatment response in anti–PD-1 naive melanoma patients, indicating potential benefits.

Abstract

Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ribas et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a2198b https://doi.org/10.1158/1078-0432.30255671

View Full Paper

Ask AI

Bookmark

Implication

Open-label trial assessed treatment response in anti–PD-1 naive melanoma patients, indicating potential benefits.

Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading